April 9, 2020

Positive Data Generated by BioSig Subsidiary ViralClear on COVID-19 Coronavirus Published in bioRxiv

Westport, CT, April 09, 2020 (GLOBE NEWSWIRE) --

- *Vicromax™ shown to decrease viral production of COVID-19 coronavirus by over 98%*
- *Article highlights recent work done in laboratory studies of COVID-19 withVicromax at the Galveston National Laboratory at The University of Texas Medical Branch*

BioSig Technologies, Inc. (NASDAQ: BSGM) ("BioSig" or the "Company"), a medical technology company commercializing a proprietary biomedical signal processing platform, today announced that an article titled, "The IMPDH inhibitor merimepodib suppresses the SARS-CoV-2 replication in vitro" to bioRxiv, an online archive and distribution service for reprints in the life sciences. This manuscript is authored by Natalya Bukreyeva, Emily K Mantlo, Rachel A Sattler, Cheng Huang, Slobodan Paessler of the UTMB Galveston National Laboratory and Dr. Jerome Zeldis of ViralClear.

The article is the first public disclosure of pre-clinical data generated under contract with Galveston National Laboratory at The University of Texas Medical Branch. The work was started with Trek Therapeutics and after Vicromax was acquired by ViralClear Pharmaceuticals, Inc. ("ViralClear"), the work continues under contract with ViralClear.

"Oftentimes if an antiviral agent such as Vicromax decreases viral production by over 90% as is presented in this article, it will have meaningful activity in the clinic," said Dr. Zeldis, ViralClear's Executive Chair and founder. "More data will be submitted to peer review journals over the coming weeks and we are looking forward to submission of our IND to the FDA and advancing to human trials with this potential therapeutic."

Vicromax™, a broad-spectrum anti-viral candidate, demonstrated strong activity against COVID-19 in cell cultures in laboratory testing. The pharmaceutical is currently undergoing extensive pre-clinical testing. The Company intends to pursue development of this agent for the treatment of COVID-19 through FDA-approved clinical trials in Q2 2020.

To view the article in its entirety, please use this link:

https://www.biorxiv.org/content/10.1101/2020.04.07.028589v1

About BioSig Technologies
BioSig Technologies is a medical technology company commercializing a proprietary

biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals (www.biosig.com).

The Company's first product, PURE EP(tm) System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing of electrocardiographic and intracardiac signals for patients undergoing electrophysiology (EP) procedures in an EP laboratory.

Forward-looking Statements
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our products and product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to market our products and product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133

Source: BioSig Technologies, Inc.